![](jpg/gettyimages-1280895783-150x150.jpg)
Exscientia
-
Artificial Intelligence, BioPharma
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.
-
Don’t miss the MedCity INVEST PharmaTech virtual conference July 26
The conference highlights the convergence of digital health and drug development. Among the panel discussions are a focus on the state of AI in drug discovery and the future of digital medicines. A startup pitch contest spotlights companies seeking to improve clinical trials. Register for free today!
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
The state of AI in drug discovery
The MedCity INVEST PhrmaTech virtual conference, scheduled for Tuesday, July 26, offers free registration and a compelling day of conversations exploring the convergence of the health tech and biopharma sectors.
-
Pharma, Artificial Intelligence, BioPharma
Sanofi bets big on AI again, paying $100M to start drug R&D pact with Exscientia
Sanofi’s new alliance with artificial intelligence biotech Exscientia spans up to 15 small molecule drugs in cancer and immunology. If drugs from the partnership reach the market, Exscientia could earn as much as $5.2 billion in milestone payments.
-
Special Reports, Artificial Intelligence
AI in healthcare has spurred exciting applications and collaboration
Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.
-
Artificial Intelligence, BioPharma
AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate
The in vivo molecule was discovered under a two-year-old partnership between the two companies to discovery drugs using artificial intelligence. It will be developed for COPD.